Suchergebnisse - "Huang, Dingzhi"

PubPharm (88)

1

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312) : A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Cheng, Y. | Fan, Y. | Zhao, Y. | +16

2

Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients

enthalten in: BMC cancer | 2024

von Wang, X. | Zhao, J. | Mei, T. | +6

3

Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy : Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Cheng, Y. | Wu, L. | Huang, D. | +22

4

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

enthalten in: Thoracic cancer | 2024

von Lin, G. | Wang, Z. | Chu, Q. | +98

5

Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma

enthalten in: BMC cancer | 2024

von Liu, W. | Du, Q. | Mei, T. | +3

6

Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma

enthalten in: BMC cancer | 2024

von Liu, W. | Du, Q. | Mei, T. | +3

7

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer

enthalten in: Thoracic Cancer | 2024

von Lin, G. | Wang, Z. | Chu, Q. | +103

8

Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma : a retrospective, multicenter study

enthalten in: BMC cancer | 2023

von Zheng, X. | Zhang, L. | Wu, L. | +38

9

Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer

enthalten in: Thoracic cancer | 2023

von Huang, D. | Lin, G. | Chu, Q. | +98

10

Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study : a case report

enthalten in: Anti-cancer drugs | 2023

von Wu, L. | Cheng, Y. | Huang, D. | +7

1
2
3
4
5
6
7
8
9
Nächster »
[9]